Ridaforolimus

Drug Profile

Ridaforolimus

Alternative Names: AP23573; BioNIR; Deforolimus; EluNIR; MedJ-01; MK-8669; NirSupreme; Ridaforolimus eluting coronary stent system

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Medinol; Merck & Co
  • Class Antineoplastics; Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary artery restenosis
  • Preregistration Submission Withdrawal Sarcoma
  • Discontinued Breast cancer; Cancer; Endometrial cancer; Neurodegenerative disorders; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 16 Jan 2017 Phase-III clinical trials in Coronary artery restenosis in Japan (Intra-arterial) (NCT02828917)
  • 21 Dec 2016 Efficacy and adverse events data from the phase II BIONICS and NIREUS trial in Coronary artery restinosis released by Medinol
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top